Profit From The Biotech Boom With Vectura Group PLC, Hikma Pharmaceuticals Plc And Indivior PLC

Vectura Group PLC (LON:VEC), Hikma Pharmaceuticals Plc (LON:HIK) and Indivior PLC (LON:INDV) are three top plays on the biotech boom.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After a record-breaking 2014, 2015 is shaping up to be another momentous year for biotech. 

During the first few months of 2015 to the beginning of March, the value of M&A deals in the pharma sector hit $59.3bn, up 94% year on year. Over the past four weeks, at least four more multi-billion dollar deals have been announced. 

And for investors that are looking to play this trend, three of the best picks are Vectura (LSE: VEC), Hikma Pharmaceuticals (LSE: HIK) and Indivior (LSE: INDV). 

In demand 

Early-stage respiratory drug specialist Vectura has struggled to impress over the past five years, but the company is finally starting to show signs of progress. 

The company has sealed a number of deals with key partners over the past 12 months. These include a collaboration deal for the company’s latest asthma product, VR506, signed with an undisclosed US partner. And a global development and licence agreement with Janssen Biotech Inc, a unit of US healthcare group Johnson & Johnson.

What’s more, Vectura has nine products in its pipeline, which are expected to come to market during 2021.  

As Vectura’s deals add up, City analysts expect the group to report a pre-tax profit of £1.6m this year — its first profit for several years. Then, during 2016 and 2017, City analysts expect Vectura’s earnings to take off. Analysts expect the company’s earnings to expand by 200% during 2016 and 260% during 2017.

Generic producer 

Generic drug production is one of the biotech market’s hottest industries. Indeed, as consumers around the world switch to low-cost generic drugs to combat ever-higher medical bills, generic producers have struggled to meet demand.

Hikma is one of the companies that has been able to benefit from this trend. 

Over the past five years Hikma’s earnings have tripled and the company has recently been promoted to the FTSE 100 index. That said, earnings are set to contract by 7% this year, although during 2016, City analysts believe that Hikma’s earnings will rebound by 18%, more than making up for this year’s decline.

Hikma is currently trading at a 2016 P/E of 19.7, compared to the biotech sector average P/E of 31.

Unwanted spin-off

Reckitt Benckiser‘s spin-off Indivior is probably one of the cheapest biotech companies in the world. After failing to find a buyer for Indivior, Reckitt spun the company off at an astonishingly low valuation, due to the fact that Indivior’s sales were coming under pressure from generic competitors.

Unfortunately, City analysts expect the company’s sales to remain under pressure for some time.  Revenue fell 8% during 2014 and is set to fall another 4% this year. Nevertheless, due to these low expectations Indivior is trading at a forward P/E of 14.2, around half the sector’s average valuation. The company is set to offer a dividend yield of 3% this year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves dose not own any share mentioned here. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »